Trial Profile
A 24-week, Randomized, Double-blind, Active-controlled, Parallel Group Trial to Assess the Superiority of Oral Linagliptin and Metformin Compared to Linagliptin Monotherapy in Newly Diagnosed, Treatment-naive, Uncontrolled Type 2 Diabetes Mellitus Patient
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 Oct 2013 New source identified and integrated (Sri Lanka Clinical Trials Registry, SLCTR2012-004).
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2013 Planned number of patients changed from 317 to 316 as reported by ClinicalTrials.gov.